US FDA declines to approve expanded use of Alnylam's heart-disease drug
Oct 9 (Reuters) - The U.S. Food and Drug Administration has declined to approve the expanded use of Alnylam Pharmaceuticals' drug to treat a rare and fatal heart disease, citing insufficient evidence of clinical meaningfulness, the company said on Monday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)